Bolt Biotherapeutics vs Entrada Therapeutics
Entrada Therapeutics is the larger business, with $25.4m of revenue in fiscal 2025 against $7.7m for Bolt Biotherapeutics (3.3 times as much). Bolt Biotherapeutics grew faster (0.1% against -87.9%). Bolt Biotherapeutics kept more of each dollar of sales as profit: a net margin of -433.7% against -565.5%. Bolt Biotherapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Bolt BiotherapeuticsBOLT, 2025 | Entrada TherapeuticsTRDA, 2025 |
|---|---|---|
| Revenue | $7.7m | $25.4m |
| Revenue growth | 0.1% | -87.9% |
| Net income | −$33.4m | −$144m |
| Operating margin | -469.3% | -621.1% |
| Net margin | -433.7% | -565.5% |
| Return on equity | -79.7% | -39.1% |
| Free cash flow | −$39.9m | −$130m |
| Cash | $11.7m | $90.4m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 23 | 152 |
| Market value | $12.7m | $185m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | — |
| Insider trades, 12 months | 4 buys, 9 sales | 17 buys, 44 sales |